Compare VERA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | LIVN |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2021 | 2015 |
| Metric | VERA | LIVN |
|---|---|---|
| Price | $37.22 | $79.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $81.30 | $72.43 |
| AVG Volume (30 Days) | ★ 2.5M | 698.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | $472.48 | $6.63 |
| P/E Ratio | ★ N/A | $198.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.07 | $41.02 |
| 52 Week High | $56.05 | $85.27 |
| Indicator | VERA | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 48.50 |
| Support Level | $32.48 | $61.63 |
| Resistance Level | $38.59 | $80.96 |
| Average True Range (ATR) | 2.75 | 2.15 |
| MACD | -0.78 | -0.73 |
| Stochastic Oscillator | 11.67 | 19.58 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.